ClinicalTrials.gg

Program

Dipyrone

Also written as “dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg”, “dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg” and “Metamizole”.

Its studies are mostly in Nasal Obstruction · Stroke · Migraine Disorders · Fever, led by 2 companies.

Furthest: phase 4, since Jul 8, 20144 company-led studies, 1 open or runningNext primary completion: Jun 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim20 open or runningphase 4since Jul 8, 2014Jul 4, 2014none ahead
Hypera Pharma21 open or runningphase 4since May 20, 2011May 20, 2011Jun 28, 2027phase 3 · NCT07626437

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2011First study: phase 4 study in FeverNew to Hypera PharmaHypera Pharma · NCT01359020 · 396 enrolled · Brazil
  2. Jul 4, 2014Boehringer Ingelheim's first study: phase 3 study in Migraine DisordersNew to Boehringer IngelheimBoehringer Ingelheim · NCT02183220 · 417 enrolled
  3. Jul 8, 2014Phase 4 study in StrokeBoehringer Ingelheim · NCT02184260 · 58 enrolled
  4. May 19, 2026Phase 3 study in Nasal ObstructionHypera Pharma · NCT07626437 · 620 planned · Brazil

Ahead

  1. Jun 28, 2027Primary completion: phase 3 study in Nasal ObstructionHypera Pharma · NCT07626437

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07626437Nasal Obstruction · Brazil3RecruitingHypera PharmaJun 28, 2027620
NCT02184260Stroke4TerminatedBoehringer IngelheimMay 200258
NCT02183220Migraine Disorders3CompletedBoehringer IngelheimJul 1999417
NCT01359020Fever · Brazil4CompletedHypera PharmaMar 2008396

How it is read

Names in the registry

  • “dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg”, 1 entry
  • “dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg”, 1 entry
  • “Metamizole”, 1 entry
  • “Metamizol”, 1 entry
  • “ibuprofen, dipyrone, acetaminophen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.